106 related articles for article (PubMed ID: 31489625)
1. Epigenetic targeting in mantle cell lymphoma.
Dunleavy K
Br J Haematol; 2019 Sep; 186(6):805-806. PubMed ID: 31489625
[No Abstract] [Full Text] [Related]
2. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
LeBlanc FR; Hasanali ZS; Stuart A; Shimko S; Sharma K; Leshchenko VV; Parekh S; Fu H; Zhang Y; Martin MM; Kester M; Fox T; Liao J; Loughran TP; Evans J; Pu JJ; Spurgeon SE; Aladjem MI; Epner EM
Oncotarget; 2022; 13():986-1002. PubMed ID: 36093297
[TBL] [Abstract][Full Text] [Related]
3. Current approaches to epigenetic therapy for the treatment of mantle cell lymphoma.
Ghai V; Sharma K; Abbi KK; Shimko S; Epner EM
Adv Exp Med Biol; 2013; 779():257-66. PubMed ID: 23288643
[TBL] [Abstract][Full Text] [Related]
4. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
Ahmed M; Zhang L; Nomie K; Lam L; Wang M
Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
[TBL] [Abstract][Full Text] [Related]
5. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
6. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.
Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM
Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
Chim CS; Wong KY; Loong F; Lam WW; Srivastava G
Hum Pathol; 2007 Dec; 38(12):1849-57. PubMed ID: 17900658
[TBL] [Abstract][Full Text] [Related]
8. Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma.
Campo E
Hum Pathol; 2003 Apr; 34(4):330-5. PubMed ID: 12733111
[No Abstract] [Full Text] [Related]
9. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
12. Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape.
Sadeghi L; Wright AP
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200679
[TBL] [Abstract][Full Text] [Related]
13. Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.
Sakai T; Masaki Y; Otsuki N; Sakamaki I; Kishi S; Miyazono T; Urasaki Y; Murakami J; Satoh T; Nakamura T; Iwao H; Nakajima A; Kawanami T; Miki M; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Ueda T
Med Oncol; 2015 Sep; 32(9):232. PubMed ID: 26275804
[TBL] [Abstract][Full Text] [Related]
14. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway.
Chim CS; Wong KY; Loong F; Srivastava G
Leukemia; 2004 Feb; 18(2):356-8. PubMed ID: 14614518
[No Abstract] [Full Text] [Related]
15. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
16. Properties of the mantle cell and mantle cell lymphoma.
Frater JL; Hsi ED
Curr Opin Hematol; 2002 Jan; 9(1):56-62. PubMed ID: 11753079
[TBL] [Abstract][Full Text] [Related]
17. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
[TBL] [Abstract][Full Text] [Related]
18. Prolymphocytic leukemia or prolymphocytic transformation of mantle cell lymphoma.
Veillon DM; Nordberg ML; Glass J; Sattar T; Cotelingam JD
Am J Clin Pathol; 2001 Nov; 116(5):781-2. PubMed ID: 11710698
[No Abstract] [Full Text] [Related]
19. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
